Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Leases Loans and Notes Receivables Long-Term Debt Issuances Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares Issued Shares Outstanding Shares Outstanding

Ratios

Terns Pharmaceuticals (TERN) Short-Term Debt repayments (2021)

Terns Pharmaceuticals filings provide 1 years of Short-Term Debt repayments readings, the most recent being $12.9 million for Q1 2021.

Quarterly Short-Term Debt repayments changed N/A to $12.9 million in Q1 2021 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Dec 2021, changed N/A year-over-year, with the annual reading at $12.9 million for FY2021, N/A changed from the prior year.
Short-Term Debt repayments hit $12.9 million in Q1 2021 for Terns Pharmaceuticals.
Across five years, Short-Term Debt repayments topped out at $12.9 million in Q1 2021 and bottomed at $12.9 million in Q1 2021.